Treatment of Skin Disease: Comprehensive Therapeutic Strategies 5th Edition PDF Free Download
Every four years, as we plan the next edition of Treatment of Skin Disease, the editors ask ourselves these questions: Do we need another edition? Has enough changed in the practice of dermatology to justify all the work needed for another edition? Thanks to extraordinary advances in our specialty, the answer has always been an emphatic yes. The last four years has seen dramatic changes in the treatment of common dermatologic conditions like psoriasis and atopic dermatitis. Anti-IL-17 antibodies were only investigational four years ago, and now two, secukinumab and ixekizumab, are approved and a third antibody to the IL-17 receptor, brodalumab, has also been approved and is about to enter the market for psoriasis. Pure anti-IL-23 antibodies were only in experimental stages based on the earlier success of ustekinumab which blocks both IL-23 and IL-12. Guselkumab has now been released and tildrakizumab has completed phase III trials and will hopefully be approved in the coming months. Another anti-IL-23 antibody, risankizumab, is already in phase III trials and has very promising results in phase II, and other anti-IL-23 antibodies are already in development for psoriasis. Dupilumab, an anti-IL-4/IL-13 antibody has just been approved for moderate to severe atopic dermatitis, and crisaborole, a topical phosphodiesterase 4 inhibitor has been introduced for the treatment of mild to moderate atopic dermatitis. Tofacitinib, a janus kinase inhibitor, has shown substantial efficacy in psoriasis and atopic dermatitis, though regulators have not allowed approval for those diseases thus far
